The hemagglutinin-neuraminidase (HN) gene sequence was determined for 16 antigenic variants of human parainfluenza virus type 3 (PIV3). The variants were selected by using monoclonal antibodies (MAbs) to 
Human parainfluenza virus type 3 (PIV3) appears to be endemic in all areas of the world and is a significant cause of acute bronchiolitis and pneumonia in infants (5) . Because of this important role in childhood illness, we are interested in developing an effective vaccine for PIV3. Since antibodies directed to the surface glycoproteins of other paramyxoviruses play a major role in prevention of infection in vitro and in vivo (14, 15) , we studied the hemagglutininneuraminidase (HN) glycoprotein of PIV3 by constructing operational and topological antigenic maps by using monoclonal antibodies (MAbs) (6, 7) . Competitive-binding radioimmunoassays identified six topographically distinct antigenic sites on the PIV3 HN glycoprotein (A to F). MAbs which neutralize virus infectivity and inhibit hemagglutination defined eleven unique epitopes which are located in antigenic sites A, B, and C. MAbs to several site A epitopes also inhibited neuraminidase activity when the small substrate N-acetyl neuraminylactose was used, suggesting that site A is located on the HN molecule in a region topographically close to the sialidase active site. Three additional antigenic sites (D, E, and F) were detected by anti-HN MAbs which do not neutralize infectivity or inhibit either hemagglutination or neuraminidase activities.
Several MAbs to site A epitopes cross-neutralize the bovine PIV3 strain. To identify the amino acids important for the integrity of those shared epitopes, we recently sequenced the HN genes of antigenic variants selected in the presence of those cross-reactive MAbs and compared them with the sequences of the HN genes of the parental human PIV3 and of the bovine virus (7) . As (7) .
RESULTS
Sequence changes in variants selected with MAbs which inhibit hemagglutination and neuraminidase activities. The coding sequences of the HN genes of the antigenic variants were determined, and a single-point mutation was found in each case. The nucleotide changes and deduced amino acid substitutions in these variants, as well as those described previously (7) , are shown in Table 1 isolates with differences in their HN epitopes to identify additional residues which may participate in these epitopes.
There are two strong parallels between the influenza virus NA and the paramyxovirus HN proteins: the N-terminal anchorage sequence and similar enzymatic functions. The HN possesses the additional function of hemagglutination, which has also recently been described for the NA of the N9 subtype of influenza virus (13) . These similarities have prompted speculation that the HN and NA genes may have evolved from a common ancestral gene (4 (16) . The present study indicates that PIV3 HN MAbs which inhibit hemagglutination and neuraminidase activities or only hemagglutination select mutations which appear to cluster in different segments of the HN molecule, but their relative locations on the three-dimensional molecule remain to be determined.
Computer-assisted analysis of the HN protein predicts that the molecule will have a secondary structure of alternating hydrophobic ,B sheets and hydrophilic random coilturn topology, but very little a-helix content. This relatively unusual structure is also characteristic of the influenza NA (17) . A recent comparison of predicted secondary structures of the HN proteins of four paramyxoviruses revealed that one region in particular was highly conserved structurally and that it strongly resembled the sialic acid-binding site of the influenza NA (E. Jorgensen and P. T. Lomedico, submitted for publication). This region corresponds to residues 234 to 323 of the PIV3 HN, and to residues 208 to 287 of the N2 NA. MAbs which inhibit influenza virus neuraminidase activity with N-acetyl neuraminylactose select NA variants with substitutions in this area (positions 221 and 253) (1, 18 ). The present study shows that two MAbs which inhibit PIV3 neuraminidase activity with N-acetyl neuraminylactose or fetuin select variants with mutations in the corresponding PIV3 HN sequence (positions 278 and 281). Furthermore, MAbs to the Sendai virus HN protein which inhibit neuraminidase activity also select variants with mutations in this region (S. Thompson and A. Portner, personal communication). These results reinforce the idea that the functional domains of the HN and NA proteins are structurally similar, but confirmation awaits the determination of the three-dimensional structure of the HN molecule by crystallography.
